Business Wire

Infobip integrates Google Vertex AI into RCS to offer conversational AI

Share

Global communications platform Infobip now offers businesses and brands access to conversational AI and AI-enabled chatbots on RCS Business Messaging through a new integration with Google Vertex AI. As pioneers in global omnichannel communications, Infobip is leading the market with innovative solutions.

As consumers look for a deeper connection with the brands they buy from, rich conversational messaging channels such as RCS Business Messaging are growing quickly. However, businesses and brands need to be able to offer advanced communications services such as conversational AI and chatbots to deliver personal, relevant, and conversational messaging experiences to their customers.

Now with RCS Google Vertex AI, businesses cancreate conversational experiences and chatbots for their customers that enhance engagement and drive conversions. By leveraging AI capabilities within RCS, Infobip empowers businesses to automate processes, provide personalized, instant support, and deliver tailored interactions, ultimately improving ROI, customer satisfaction, and loyalty.

Ivan Ostojić, Chief Business Officer at Infobip, said:“RCS is one of the key communication channels that businesses and brands are increasingly using to communicate with their customers given its ability to provide a rich experience natively available on customer phones. As experts in omnichannel messaging and with an unmatched portfolio of telecom partners across the globe, we can ensure that RCS messages, and messages across any other channel, are safely and securely delivered to customers everywhere. The combination of our RCS expertise and partner network, the power of Google’s Vertex AI, and client industry knowledge and customer insights guarantee conversational RCS interactions that will help set brands apart from their competition.”

Google Vertex AI is a machine learning (ML) platform developed by Google Cloud. It helps software providers to easily build, train, and manage ML models and AI applications by providing all the tools and services required in a single platform.

Building an RCS chatbot with Vertex AI will enable businesses and brands to create intelligent bots that can deal with a range of queries, transactions, and customer support issues across the entire customer lifecycle. Rather than building separate chatbots for each use case, all can be serviced in a single messaging thread on RCS Business Messaging.

About Infobip

Infobip is a global cloud communications platform that enables businesses to build connected experiences across all stages of the customer journey.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619244090/en/

Contacts

Andrej Mendaš
Global Corporate PR Manager
Andrej.Mendas@infobip.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 20258.3.2025 16:00:00 CET | Press Release

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83rd American Academy of Dermatology (AAD) 2025 Annual Meeting.1 The presentation marks the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data has also been shared for delgocitinib cream at the meeting.2 “The data unveiled today further contributes to LEO Pharma’s ever-growing body of scientific evidence for the treatment of moderate to severe CHE,” said Christophe Bourdon, Chief Executive Officer, LEO Pharma. “Our research and work in CHE is a testament to our ambition to maintain the broadest global product portfolio in dermatology, and I am proud we can share this latest analysis from our pivotal DELTA trials.” Delgocitinib cream is currently under investigation in the United States. Late-Breaking Post Hoc Data Analysis The sub

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura ® ) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting8.3.2025 15:01:00 CET | Press Release

Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. The TRuE-PN1 study met its primary endpoint demonstrating that significantly more PN patients who applied ruxolitinib cream 1.5% versus vehicle control achieved a ≥4-point improvement from baseline in Worst-Itch Numeric Rating Scale (WI-NRS4) at Week 12 (44.6% vs 20.6%; P=0.0003). Significant itch improvements were observed with ruxolitinib cream 1.5% versus vehicle control at Day 7 (22.4% vs 8.0%; P=0.0064), with numerical improvements versus v

Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research7.3.2025 20:16:00 CET | Press Release

Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website (ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, from basic research to the design of novel therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307777605/en/ On the Proteintech website (ptglab.com), researchers can explore antibody binding sites with the new interactive 3D epitope viewer. (Photo: Business Wire) The 3D Epitope Mapping is a state-of-the-art solution that utilizes a combination of experimental techniques, including peptide scanning and microbial display, aiming to precisely map the antibody binding site (epitope) on a target protein. This mapping is then visualized

I Squared Capital Appoints Philippe Lenoble and Bogdan Ciobotaru as Managing Directors7.3.2025 16:32:00 CET | Press Release

I Squared Capital, a leading independent global infrastructure investment firm, today announced two senior appointments to its investment and asset management teams in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306212222/en/ Philippe Lenoble, Managing Director, I Squared (Photo: Business Wire) Philippe Lenoble will join the investment team as Managing Director, reporting to Mohamed El Gazzar, Senior Partner. Bogdan Ciobotaru will join the asset management team as Managing Director reporting to Maxime Jacqz, Managing Director, who leads asset management in Europe. The demands for new and improved infrastructure requires investors to balance the increasing opportunities with the right resourcing to manage the increased scale and complexity. I Squared is committed to expanding its investment and asset management capabilities in a thoughtful and deliberate way to seize this opportunity and deliver value for its pa

Vertex Announces UK MHRA Approval of ALYFTREK ® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis7.3.2025 16:02:00 CET | Press Release

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor),a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. “For more than 20 years we have been focused on discovering medicines that treat the underlying cause of the disease with the goal of helping people live longer and better lives. The approval of ALYFTREK, our fifth CFTR modulator regimen, represents another significant milestone in that journey for people with CF in the UK,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “The deutivacaftor/tezacaftor/vanzacafto

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye